Qiagen is a diagnostics & research business based in the US. Qiagen shares (QGEN) are listed on the NYSE and all prices are listed in US Dollars. Qiagen employs 5,700 staff and has a trailing 12-month revenue of around $2.1 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Qiagen stock price (NYSE: QGEN)
Use our graph to track the performance of QGEN stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Qiagen stock undervalued or overvalued?
Valuing Qiagen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Qiagen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Qiagen's P/E ratio
Qiagen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Qiagen shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Qiagen's PEG ratio
Qiagen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3274. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Qiagen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Qiagen's EBITDA
Qiagen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 billion.
The EBITDA is a measure of a Qiagen's overall financial performance and is widely used to measure a its profitability.
Qiagen financials
Revenue TTM
$2.1 billion
Operating margin TTM
25.78%
Gross profit TTM
$1.7 billion
Return on assets TTM
8.19%
Return on equity TTM
11.29%
Profit margin
19.58%
Book value
$16.83
Market Capitalization
$10.3 billion
TTM: trailing 12 months
Qiagen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Qiagen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Qiagen's total ESG risk score
Total ESG risk: 16.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Qiagen's overall score of 16.36 (as at 12/31/2018) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Qiagen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Qiagen's environmental score
Environmental score: 1.25/100
Qiagen's environmental score of 1.25 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Qiagen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Qiagen's social score
Social score: 8.53/100
Qiagen's social score of 8.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Qiagen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Qiagen's governance score
Governance score: 6.07/100
Qiagen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Qiagen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Qiagen's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Qiagen scored a 1 out of 5 for controversy – the highest score possible, reflecting that Qiagen has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Qiagen NV was last rated for ESG on: 2019-01-01.
Total ESG score
16.36
Total ESG percentile
13.68
Environmental score
1.25
Environmental score percentile
2
Social score
8.53
Social score percentile
2
Governance score
6.07
Governance score percentile
2
Level of controversy
1
Qiagen share dividends
Dividend payout ratio: 63.71% of net profits
Recently Qiagen has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Qiagen shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Qiagen's case, that would currently equate to about $0.25 per share.
Qiagen's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Qiagen's most recent dividend payout was on 9 July 2025. The latest dividend was paid out to all shareholders who bought their shares by 1 July 2025 (the "ex-dividend date").
Have Qiagen's shares ever split?
Qiagen's shares were
split on a 962:1000 basis on 24 January 2017
. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 962 shares. This wouldn't directly have changed the overall worth of your Qiagen shares – just the quantity. However, indirectly, the new 4% higher share price could have impacted the market appetite for Qiagen shares which in turn could have impacted Qiagen's share price.
Qiagen share price volatility
Over the last 12 months, Qiagen's shares have ranged in value from as little as $37.4349 up to $51.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Qiagen's is 0.677. This would suggest that Qiagen's shares are less volatile than average (for this exchange).
Qiagen overview
Qiagen N. V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services.
Frequently asked questions
What percentage of Qiagen is owned by insiders or institutions? Currently 0.447% of Qiagen shares are held by insiders and 83.421% by institutions.How many people work for Qiagen? Latest data suggests 5,700 work at Qiagen.When does the fiscal year end for Qiagen? Qiagen's fiscal year ends in December.Where is Qiagen based? Qiagen's address is: Hulsterweg 82, Venlo, Netherlands, 5912 PLWhat is Qiagen's ISIN number? Qiagen's international securities identification number is: NL0015002CX3What is Qiagen's CUSIP number? Qiagen's Committee on Uniform Securities Identification Procedures number is: N72482123
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
